Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 12Ovarian Neoplasms 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Sarcoma 7Colorectal Neoplasms 7Prostatic Neoplasms 6Fallopian Tube Neoplasms 6Neoplasm Metastasis 5Lymphoma 5Head and Neck Neoplasms 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Osteosarcoma 4Neoplasms 4Leukemia, Myeloid, Acute 4Central Nervous System Neoplasms 4Burkitt Lymphoma 4Stomach Neoplasms 3Sezary Syndrome 3Salivary Gland Neoplasms 3Rhabdoid Tumor 3Rectal Neoplasms 3Pain 3Neuroectodermal Tumors, Primitive, Peripheral 3Mycosis Fungoides 3Melanoma 3Lymphoma, T-Cell, Cutaneous 3

Interventions

vatalanib 1Octreotide 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × NETWORK × Vipoma × Clear all
NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡